IntelliAM aiming for significant growth with £5 million Aquis IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,035.00
Bid: 4,059.00
Ask: 4,062.00
Change: -55.00 (-1.34%)
Spread: 3.00 (0.074%)
Open: 4,098.00
High: 4,120.00
Low: 4,035.00
Prev. Close: 4,090.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Appointment

6 Feb 2012 14:00

RNS Number : 8693W
Croda International PLC
06 February 2012
 



6 February 2012

 

Croda International Plc

 

Appointment of Chief Technology Officer

Croda International Plc, the speciality chemicals company, is pleased to announce that Keith Layden has been appointed to the Board as an executive director with immediate effect, in the new role of Chief Technology Officer.

Keith joined Croda in 1984 and for the past 7 years has been President of our Enterprise Technology and Actives businesses, where he has overseen significant growth in innovation and expansion into new product areas. Prior to this he held a number of Managing Director roles across our European business. As Chief Technology Officer, Keith will be responsible for accelerating the identification, development, licensing and acquisition of innovative technologies, the global co-ordination of Croda's R&D activities and the development of novel production processes for our major existing core product platforms.

Steve Foots, Croda's Chief Executive, commented,

"Keith's appointment to the Board is recognition of the importance the capture of external technologies is to our short and medium term growth plans. This is an exciting new role for Keith and the organisation."

Martin Flower, Croda's Chairman, commented,

 "We are delighted that Keith has joined the Croda Board in this important new role. His wealth of experience of the chemical industry and its related technologies will be of great value during the next phase of Croda's development. "

 

There are no further matters to be disclosed under LR9.6.13R of the Listing Rules of the UK Listing Authority.

Enquiries:

Ben Foster, Pendomer Communications

020 3603 5221

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOABXGDDCBGBGDL
Date   Source Headline
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director
3rd Nov 20225:53 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:51 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:50 pmRNSDirector/PDMR Shareholding
3rd Nov 20225:49 pmRNSDirector/PDMR Shareholding
11th Oct 20221:37 pmRNSDirector/PDMR Shareholding
7th Oct 20228:37 amRNSDirector/PDMR Shareholding
7th Oct 20227:59 amRNSDirector/PDMR Shareholding
7th Oct 20227:00 amRNSInvestor seminar
5th Oct 20224:42 pmRNSDirector/PDMR Shareholding
20th Sep 20229:01 amRNSDirector/PDMR Shareholding
13th Sep 20221:47 pmRNSDirector/PDMR Shareholding
11th Aug 20222:39 pmRNSDirector/PDMR Shareholding
29th Jul 20227:00 amRNSResults for the six months ended 30 June 2022
22nd Jul 20224:50 pmRNSDirectorate Change
12th Jul 20223:08 pmRNSDirector/PDMR Shareholding
1st Jul 20227:00 amRNSCompleted divestment
30th Jun 202212:15 pmRNSTotal Voting Rights
28th Jun 20227:00 amRNSUS Government to support lipid systems expansion
22nd Jun 20229:07 amRNSHolding(s) in Company
17th Jun 20229:46 amRNSHolding(s) in Company
13th Jun 20222:52 pmRNSDirector/PDMR Shareholding
8th Jun 202211:53 amRNSDirector/PDMR Shareholding
7th Jun 20225:23 pmRNSTransaction in Own Shares
7th Jun 20224:08 pmRNSDirector/PDMR Shareholding
7th Jun 20223:27 pmRNSHolding(s) in Company
27th May 202210:48 amRNSHolding(s) in Company
26th May 20227:02 amRNSDirector Declaration
23rd May 20222:34 pmRNSResult of AGM
20th May 20227:21 amRNSAGM trading update
19th May 20223:09 pmRNSDirector/PDMR Shareholding
19th May 20222:17 pmRNSHolding(s) in Company
11th May 20222:15 pmRNSDirector/PDMR Shareholding
11th May 20227:00 amRNSSite visit and investor presentation
3rd May 202210:21 amRNSDirector/PDMR Shareholding
13th Apr 20229:48 amRNSDirector/PDMR Shareholding
7th Apr 20226:15 pmRNSDirector/PDMR Shareholding
31st Mar 20223:12 pmRNSUK Government to support lipid systems expansion
29th Mar 20227:00 amRNSInvestor seminar
22nd Mar 20226:14 pmRNSAnnual Financial Report
22nd Mar 20224:49 pmRNSDirector/PDMR Shareholding
16th Mar 20225:21 pmRNSDirector/PDMR Shareholding
16th Mar 20225:20 pmRNSDirector/PDMR Shareholding
16th Mar 20225:19 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:15 pmRNSDirector/PDMR Shareholding
16th Mar 20225:13 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding
16th Mar 20225:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.